Company intelligence / Profile preview

Primorigen Biosciences

Madison, Wisconsin, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Primorigen Biosciences did not develop therapeutic drugs; it produced recombinant human proteins and xeno‑free extracellular matrix reagents such as Vitronectin XF for stem cell and cell/gene therapy research.[1][4][5]

Modalities: Recombinant protein
Industry: Non-Drug Biotech

Partnerships

Nucleus Biologics (acquirer and commercializer of Vitronectin XF and related products)[4][5]

Beyond the preview

Go deeper on Primorigen Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primorigen Biosciences.

Explore the full profile